Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
GLIBENCLAMIDE
Sanofi-Aventis Ireland Limited T/A SANOFI
GLIBENCLAMIDE
5 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
_créé le_ _par_ _modifié le_ _par_ _Laboratoires_ _Pays_ 12/05/2014 E WASCZCZYK 15/07/2014 E WASCZCZYK SANOFI IRLANDE _Couleur_ _Nbre/Réf._ 1 BLEU REFLEX BLUE U _Version N°_ 2 _Type Article_ NOTICE TRIPLE DAONIL R772290 5 MG CPRS _Nom du produit_ _Référence article_ _Dosage_ _Quantité_ _N° version Logo/Name_ _N° version Country Ex._ _N° plan Dimensionnel_ _N° plan positionnement_ _Dimensions_ _Taille mini caractères_ A1 - 11.04.2006 CRIE - V1 - 09/2012 1-606251A 606251-1A 150 X 210 MM 9 PTS _Numéro de Pages_ 1 / 6 _Code sécurité_ R772290 COMPIÈGNE COMPIÈGNE frequent urination and muscular stiffness) • You are in a diabetic coma • You are pregnant • You are breast-feeding • You have severe problems with your kidneys • You have a severe liver disease • You are receiving a medicine called bosentan, used to treat high blood pressure Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Daonil. WARNINGS AND PRECAUTIONS TAKE SPECIAL CARE WITH DAONIL CHECK WITH YOUR DOCTOR OR PHARMACIST BEFORE TAKING YOUR MEDICINE IF: • You are recovering from an injury, operation, infections with fever, or from other forms of stress, inform your doctor as temporary change of treatment may be necessary • You have a severe liver or kidney disorder If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Daonil. Lowering of the haemoglobin level and breakdown of red blood cells (haemolytic anemia) can occur in patients missing the enzyme glucose-6-phosphate dehydrogenase. The information available on the use of Daonil in people under 18 years of age is limited. Therefore Daonil is not recommended for use in children. 1. WHAT DAONIL IS AND WHAT IT IS USED FOR The name of your Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Daonil 5 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Glibenclamide 5mg. Excipients: contains Lactose Monohydrate 79.0mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet White biplane, oblong tablets with ‘LDI’ engraved on each side of scoreline and inverted on one side, the other side is plain. The score line present allows the tablet to be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Daonil is a sulphonylurea hypoglycaemic agent, indicated for the oral treatment of patients with non-insulin dependent diabetes who respond inadequately to dietary measures alone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage of glibenclamide is governed by the desired blood glucose level. The dosage of glibenclamide must be the lowest possible dose which is effective. Mistakes, e.g. forgetting to take a dose, must never be corrected by subsequently taking a larger dose. The usual total daily dosage is 2.5mg to 15mg daily with a usual initial dose of 5mg daily. Weekly adjustments can be made to increase the dosage to the optimal level. Doses of 10mg or less may be taken as a single dose immediately before breakfast, but should the daily dose exceed 10mg, the remainder should be taken immediately before the evening meal. The elderly usually require lower dosage. DOSE OMISSION A physician should be consulted in the event that a dose has not been taken at the prescribed time, a meal has been skipped or an extra dose has been taken. It is very important not to skip meals after the tablets have been taken. SECONDARY DOSAGE ADJUSTMENT As an improvement in control of diabetes is, in itself, associated with higher insulin sensitivity, glibencl Read the complete document